Health
A novel monoclonal antibody therapy cuts LDL cholesterol by half in a high-risk patient population, – EurekAlert
The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol–the so-called ”bad” cholesterol–by 50 percent in patients with severe…
The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol–the so-called “bad” cholesterol–by 50 percent in patients with severe hypercholesterolemia whose condition is resistant to standard treatments, a phase 2 study from the Icahn School of Medicine of Mount Sinai and other global academic sites has found. Results from the study sponsored by Regeneron, are being presented as “late breaking science” at the American Heart Association Scientific Sessions 2020 on Sunday,…
-
Noosa News21 hours agoFlatmates of missing teen Pheobe Bishop, 17, identified
-
Noosa News23 hours agoTully Sugar Mill celebrates 100 years of cane harvesting amid floods and cyclones
-
Noosa News20 hours agoFranz Ferdinand: Australian Tour 2025
-
General20 hours agoPostecoglou’s message touches Blues AFL coach Voss after Spurs’ Europa League win